Squalene versus cholesterol: Which is the best nanocarrier for the delivery to cells of the anticancer drug gemcitabine?

Authors:

Abstract
It has been previously shown that the linkage of the anticancer drug gemcitabine (Gem) to the squalene (SQ), a natural lipid precursor of the cholesterol biosynthesis, allowed the resulting bioconjugates to spontaneously self-assemble as nanoparticles (NPs) with improved pharmacological activity. We show here that when the squalene moiety was replaced by the cholesterol and the conjugation performed through a carbamate linker, although rather stable nanoparticles were obtained, the in vitro anticancer activity in the human breast cancer cell line MDA-MB-231 was completely abolished. This was attributed to reduced enzymatic accessibility toward the carbamate linker, which may hamper the gemcitabine release. A lower propensity of incorporation into the plasma cell membrane, which was revealed by molecular simulations, may also play a role in lower activity of cholesterol derivative.
Funding Information
  • European Community's Seventh Framework Programme (249835)
  • CNRS
  • French Ministry of Research
  • European Union's Horizon 2020

This publication has 28 references indexed in Scilit: